Reported 2 days ago
The FDA has confirmed that Eli Lilly has resolved the shortage of its weight-loss drug Zepbound and diabetes drug Mounjaro, boosting its market position against rival Novo Nordisk, which still faces shortages with its drugs. This allows Lilly to capture a larger share of the weight-loss market, as sales increased recently, while compounding pharmacies producing copycat versions are now required to cease production in about 60 days. This situation could significantly impact market dynamics as Lilly strengthens its foothold in the pharmaceutical landscape.
Source: YAHOO